A61K 38/1787
For neuromediators
Official title: {for neuromediators, e.g. serotonin receptor, dopamine receptor}
A61K38/1787 (For neuromediators) appears on 46 US grants and 101 published applications in this corpus.
Search patents in A61K- Granted patents
- 46
- Published applications
- 101
- Assignees
- 56
- Inventors
- 214
- Latest grant
- 11 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 4 |
| 2004 | 1 | 4 |
| 2005 | 0 | 1 |
| 2006 | 1 | 1 |
| 2007 | 2 | 2 |
| 2008 | 1 | 3 |
| 2009 | 0 | 3 |
| 2010 | 1 | 3 |
| 2011 | 2 | 1 |
| 2012 | 1 | 1 |
| 2013 | 2 | 4 |
| 2014 | 0 | 2 |
| 2015 | 1 | 3 |
| 2016 | 0 | 4 |
| 2017 | 2 | 7 |
| 2018 | 2 | 2 |
| 2019 | 5 | 11 |
| 2020 | 4 | 5 |
| 2021 | 7 | 10 |
| 2022 | 3 | 4 |
| 2023 | 2 | 6 |
| 2024 | 4 | 6 |
| 2025 | 1 | 6 |
| 2026 | 0 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- α-sheet polypeptides and their use11 Mar 2025US 12,247,050 B2University of Washington
- Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-optimized SLC6A13 Sep 2024US 12,077,772 B2Board of Regents, The University of Texas System
- Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use30 Jul 2024US 12,048,696 B2Janssen Pharmaceutica NV
- Tissue catalyzed growth of polymer as epithelial linings for therapy25 Jun 2024US 12,016,901 B2Massachusetts Institute of Technology
- Combination therapy for ischemia23 Jan 2024US 11,878,044 B2NoNO Inc.
- Combination for treatment of autoimmune diseases23 Jul 2026US 2026/0207722 A1Bonsai Biotherapeutics AB
- Polypeptide and use thereof2 Jul 2026US 2026/0183408 A1Shenzhen Chenyang Biological Technology Co., Ltd
- Optimized slc52a2 polynucleotide constructs and expression cassettes11 Jun 2026US 2026/0158169 A1Board of Regents, The University of Texas System
- Treatment of diseases associated with pathologic neuronal cells4 Jun 2026US 2026/0151511 A1Modulight Bio Ltd.
- 4-phenylbutyrate restored gaba uptake and reduced seizures in slc6a1 variant-mediated disorders28 May 2026US 2026/0144769 A1Vanderbilt University
Most cited
By later US patents
- In vivo genetic modification of growth factor-responsive neural precursor cells96US 6,071,889 ANeurospheres Holdings Ltd. · 2000
- Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function45US 6,436,908 B1Duke University · 2002
- Catecholamine receptor modulation15US 8,241,903 B2Yeda Research and Development Co. Ltd. · 2012
- Co-administration of an agent linked to an internalization peptide with an anti-inflammatory8US 8,080,518 B2Arbor Vita Corporation · 2011
- Treatment for anxiety5US 8,008,253 B22011